NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Idera Pharmaceuticals, Inc. (“Idera Pharmaceuticals” or the “Company”) (NASDAQCM:IDRA) stock prior to January 22, 2018.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Idera Pharmaceuticals to BioCryst Pharmaceuticals, Inc. (NASDAQGS:BCRX). Under the terms of the transaction, Idera shareholders will receive 0.20 shares of the new company’s stock per share, while BioCryst shareholders will receive 0.50 shares of the new company’s stock per share. BioCryst shareholders will own 51.6% of the stock in the post-merger entity. To learn more about the investigation and your rights, go to:
http://www.zlk.com/mna/idera-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The investigation concerns whether the Board of Idera breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether BioCryst is underpaying for Idera shares, thus unlawfully harming Idera shareholders. An insider owning approximately 9% of Idera outstanding shares and approximately 14% of BioCryst outstanding shares has already agreed to tender his shares.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
